Objectives Delays in cancer diagnosis for patients with non-specific symptoms (NSSs) lead to poorer outcomes. Rapid Diagnostic Clinics (RDCs) expedite care, but most NSS patients do not have cancer, ...

Men face higher chronic disease rates after 40. Learn which medical tests doctors say are vital for preventing heart attacks, ...

High-sensitivity C-reactive protein (CRP) decreased significantly in the semaglutide group, with estimated treatment ratios ...

Concomitant IBD reduces disease control and treatment response among patients with PsA receiving biologic therapy.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 TRIUMPH-4 clinical trial ...

C-reactive protein (CRP) flags body-wide inflammation, from infections, or poor habits. High CRP over 3 mg/L doubles early death risk from heart disease or cancer. It also predicts lifespan in older ...

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4 trial, ...

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.

Happy relationships protect heart health as strongly as traditional risk factors, but most cardiac care ignores this ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.